In Vivo Comparison of V.A.C.® Granufoam Silver™ & V.A.C.® Granufoam™ Loaded with CZ-01179, A First-in-class bis-dialkylnorspermidine-terphenyl Antibiofilm Agent- Bioeng Transl Med
k rawson, t neuberger, t smith, i bell, n hooper, i chisolm, m parkin, r looper, p sebahar, r hayssener, h reddy, b isaacson, p pasquina, d williams
Biofilm-related infections remain a persistent challenge in chronic and traumatic wounds, particularly when delayed intervention, environmental exposure, and multidrug resistance complicate management. Many of these wounds are treated with negative pressure wound therapy (NPWT), yet current antimicrobial NPWT foams have limited antibiofilm activity. CZ-01179 is a first-in-class antibiofilm compound with demonstrated in vitro and ex vivo efficacy when incorporated into polyurethane foam for NPWT. This study evaluated CZ-01179-loaded foam in a large-scale in vivo porcine excision wound model. Full-thickness excision wounds were created on the dorsum of Yorkshire pigs and inoculated three times with mature methicillin-resistant Staphylococcus aureus (MRSA) or Acinetobacter baumannii biofilms. Wounds were treated for 7 days with 10.0% w/w CZ-01179-loaded Granufoam™, Granufoam™ alone, or Granufoam Silver™ under continuous NPWT. Natural flora growth was also assessed. Quantitative cultures were obtained from tissue biopsies, reported as Log10 colony forming units (CFU)/g tissue, and compared across groups. CZ-01179-loaded foam resulted in >3 Log10 CFU/g lower MRSA and A. baumannii bioburden than Granufoam™ or Granufoam Silver™ (p ≤ 0.00013). Similar efficacy was observed against natural polymicrobial flora. The porcine model validated robust biofilm-related infection and enabled translational assessment of an NPWT-compatible antibiofilm therapy. CZ-01179 demonstrated potent antibiofilm activity when combined with NPWT, providing in vivo confirmation of its efficacy in a clinically relevant large-animal model. Its stability, protease resistance, and hydrogel-based delivery support further development as a field-deployable therapy for complex wound infections, including combat-related wounds.
Rawson KB, Neuberger T, Smith TB, et al. In vivo comparison of V.A.C.® Granufoam Silver™ and V.A.C.® Granufoam™ loaded with CZ-01179, a first-in-class bis-dialkylnorspermidine-terphenyl antibiofilm agent, in a porcine excision model. Bioeng Transl Med. 2026;e70192. doi:10.1002/btm2.70192